These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 29621988)

  • 21. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
    Liu KC; Hao YH; Lv WF; Jia WD; Ji CS; Zhou CZ; Cheng DL; Xu SB; Gao ZG; Su MX; Shi CS
    Drug Des Devel Ther; 2020; 14():3461-3468. PubMed ID: 32904650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Parikh ND; Singal AG; Hutton DW
    Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sunitinib versus sorafenib plus transarterial chemoembolization for inoperable hepatocellular carcinoma patients.
    Xu Q; Huang Y; Shi H; Song Q; Xu Y
    J BUON; 2018; 23(1):193-199. PubMed ID: 29552783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
    Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
    JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization.
    Manas D; Bell JK; Mealing S; Davies H; Baker H; Holmes H; Hubner RA
    Eur J Surg Oncol; 2021 Feb; 47(2):401-408. PubMed ID: 32958370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?
    Kim J; Sinn DH; Choi MS; Kang W; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW
    PLoS One; 2019; 14(3):e0213547. PubMed ID: 30845192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib.
    Gao J; Liu S; Li SJ; Wang R; Meng ZH; Kong XS
    Med Sci Monit; 2024 Jul; 30():e944526. PubMed ID: 39033318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis.
    Feng F; Jiang Q; Jia H; Sun H; Chai Y; Li X; Rong G; Zhang Y; Li Z
    Pharmacol Res; 2018 Sep; 135():89-101. PubMed ID: 29959032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.
    Hamdy Elsisi G; Nada Y; Rashad N; Carapinha J
    J Med Econ; 2019 Feb; 22(2):163-168. PubMed ID: 30479174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
    Han K; Kim JH
    World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma.
    Chen S; Jin H; Dai Z; Wei M; Xiao H; Su T; Li B; Liu X; Wang Y; Li J; Shen S; Zhou Q; Peng B; Peng Z; Peng S
    Cancer Med; 2019 Apr; 8(4):1530-1539. PubMed ID: 30864247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma.
    He Y; Lin W; Cai Z; Huang Y; You M; Lei M; Chen R
    Front Pharmacol; 2023; 14():1219694. PubMed ID: 37745079
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
    Zhang P; Yang Y; Wen F; He X; Tang R; Du Z; Zhou J; Zhang J; Li Q
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):853-9. PubMed ID: 25919775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases.
    Yoo JJ; Lee JH; Lee SH; Lee M; Lee DH; Cho Y; Lee YB; Yu SJ; Kim HC; Kim YJ; Yoon JH; Kim CY; Lee HS
    PLoS One; 2014; 9(11):e113926. PubMed ID: 25427152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China.
    Li W; Wan L
    BMJ Open; 2023 Sep; 13(9):e074245. PubMed ID: 37751954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population.
    Lee SW; Tung CF; Peng YC; Lien HC; Chang CS
    J Dig Dis; 2020 Aug; 21(8):462-467. PubMed ID: 32472590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study.
    Hsiao WD; Peng CY; Chuang PH; Lai HC; Cheng KS; Chou JW; Chen YY; Yu CJ; Feng CL; Su WP; Chen SH; Kao JT
    BMC Gastroenterol; 2016 Apr; 16():50. PubMed ID: 27117280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
    Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
    Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review.
    Zhao Y; Cai G; Zhou L; Liu L; Qi X; Bai M; Li Y; Fan D; Han G
    Asia Pac J Clin Oncol; 2013 Dec; 9(4):357-64. PubMed ID: 23714021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.